NO20064864L - Spraytorkede farmasoytiske preparater - Google Patents

Spraytorkede farmasoytiske preparater

Info

Publication number
NO20064864L
NO20064864L NO20064864A NO20064864A NO20064864L NO 20064864 L NO20064864 L NO 20064864L NO 20064864 A NO20064864 A NO 20064864A NO 20064864 A NO20064864 A NO 20064864A NO 20064864 L NO20064864 L NO 20064864L
Authority
NO
Norway
Prior art keywords
spray
pharmaceutical preparations
dried pharmaceutical
dried
therapy
Prior art date
Application number
NO20064864A
Other languages
English (en)
Inventor
Vlasios Andronis
Rennan Pan
Kamlesh Rameshchandra Patel
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20064864L publication Critical patent/NO20064864L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet nye sammensetninger inneholdende NKg reseptorantagonisten talnetant, hvilke sammensetninger har forøket biotilgjengelighet. I tillegg er det beskrevet fremgangsmåter for fremstilling og anvendelser av sammensetninger innenfor terapi.
NO20064864A 2004-03-30 2006-10-25 Spraytorkede farmasoytiske preparater NO20064864L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55757104P 2004-03-30 2004-03-30
PCT/US2005/010350 WO2005097077A2 (en) 2004-03-30 2005-03-28 Spray dried pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20064864L true NO20064864L (no) 2006-10-25

Family

ID=34956393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064864A NO20064864L (no) 2004-03-30 2006-10-25 Spraytorkede farmasoytiske preparater

Country Status (26)

Country Link
US (1) US20070178151A1 (no)
EP (1) EP1729734B1 (no)
JP (1) JP2007530702A (no)
KR (1) KR20060135000A (no)
CN (1) CN1933816A (no)
AR (1) AR048193A1 (no)
AT (1) ATE387189T1 (no)
AU (1) AU2005231355B2 (no)
BR (1) BRPI0508111A (no)
CA (1) CA2556461A1 (no)
DE (1) DE602005005033T2 (no)
DK (1) DK1729734T3 (no)
ES (1) ES2301003T3 (no)
HR (1) HRP20080154T3 (no)
IL (1) IL177606A0 (no)
IS (1) IS8548A (no)
MA (1) MA28557B1 (no)
NO (1) NO20064864L (no)
NZ (1) NZ549096A (no)
PE (1) PE20060161A1 (no)
PL (1) PL1729734T3 (no)
PT (1) PT1729734E (no)
RU (1) RU2006138054A (no)
TW (1) TW200602055A (no)
WO (1) WO2005097077A2 (no)
ZA (1) ZA200606670B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007044251A2 (en) * 2005-09-30 2007-04-19 Smithkline Beecham Corporation Pharmaceutical compositions
JP2009510121A (ja) * 2005-09-30 2009-03-12 スミスクライン・ビーチャム・コーポレイション 医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
SK282721B6 (sk) * 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
US6936277B2 (en) * 1995-01-09 2005-08-30 J. Rettenmaier & Soehne Gmbh & Co. Kg Pharmaceutical excipient having improved compressibility
DE19501269A1 (de) * 1995-01-18 1996-07-25 Henkel Kgaa Amorphes Alkalisilikat-Compound
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
MY134211A (en) * 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
ES2292848T3 (es) * 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.

Also Published As

Publication number Publication date
WO2005097077A2 (en) 2005-10-20
AU2005231355A1 (en) 2005-10-20
EP1729734B1 (en) 2008-02-27
WO2005097077A3 (en) 2006-04-13
HK1099213A1 (en) 2007-08-10
TW200602055A (en) 2006-01-16
PE20060161A1 (es) 2006-05-10
US20070178151A1 (en) 2007-08-02
HRP20080154T3 (hr) 2008-10-31
NZ549096A (en) 2009-05-31
MA28557B1 (fr) 2007-04-03
DE602005005033T2 (de) 2009-03-19
DE602005005033D1 (de) 2008-04-10
PL1729734T3 (pl) 2008-09-30
KR20060135000A (ko) 2006-12-28
JP2007530702A (ja) 2007-11-01
ZA200606670B (en) 2008-01-30
PT1729734E (pt) 2008-05-29
ES2301003T3 (es) 2008-06-16
ATE387189T1 (de) 2008-03-15
RU2006138054A (ru) 2008-05-10
AR048193A1 (es) 2006-04-05
CA2556461A1 (en) 2005-10-20
EP1729734A2 (en) 2006-12-13
DK1729734T3 (da) 2008-06-16
IL177606A0 (en) 2006-12-10
AU2005231355B2 (en) 2008-09-18
CN1933816A (zh) 2007-03-21
IS8548A (is) 2006-10-06
BRPI0508111A (pt) 2007-07-17

Similar Documents

Publication Publication Date Title
ZA202103587B (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
ZA202204284B (en) Inhibitors of raf kinases
NO20091299L (no) Substituerte sulfonamidderivater
JOP20190174A1 (ar) مثبطات jak1 انتقائية
TN2009000446A1 (en) P70 s6 kinase inhibitors
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
MY187047A (en) Selective pyy compounds and uses thereof
NO20081844L (no) Terapeutiske forbindelser
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
SE0301372D0 (sv) Novel compounds
EP2617431A3 (en) Polypeptide inhibitors of HSP27 kinase and uses therefor
TW200716646A (en) (S)-N-methylnaltrexone
NO20090305L (no) Cyklosporin formuleringer
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
MY144972A (en) Novel amide derivative for inhibiting the growth of cancer cells
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
NO20065190L (no) Farmasoytiske sammensetninger omfattende en amfifil stivelse
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
TR201818814T4 (tr) Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
EA200870545A1 (ru) Новые гетероциклические соединения
WO2016065028A8 (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
MX387785B (es) Compuestos heteroarilo y su uso como farmacos terapeuticos.
NO20082130L (no) 3-Amino-1-arylpropylindoler og aza-substituerte indoler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application